Cargando…

COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing

INTRODUCTION: Inactivated, viral vector and mRNA vaccines have been used in the Nepali COVID-19 vaccination programme but there is little evidence on the effectiveness of these vaccines in this setting. The aim of this study is to describe COVID-19 vaccine effectiveness in Nepal and provide informat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bijukchhe, Sanjeev M, O'Reilly, Peter J, Theiss-Nyland, Katherine, Gurung, Meeru, Pokhrel, Bhishma, Kelly, Sarah, Acharya, Samita, Maharjan, Shreekrishna, Shrestha, Ashis, Pandey, Bimal, Lama, Mipsang, Shrestha, Ira, Voysey, Merryn, Eordogh, Agnes, Shrestha, Sonu, Feng, Elaine Shuo, Li, Grace, Shah, Ganesh, Pollard, Andrew J, Shrestha, Shrijana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123857/
https://www.ncbi.nlm.nih.gov/pubmed/37072367
http://dx.doi.org/10.1136/bmjopen-2022-068334
_version_ 1785029738271604736
author Bijukchhe, Sanjeev M
O'Reilly, Peter J
Theiss-Nyland, Katherine
Gurung, Meeru
Pokhrel, Bhishma
Kelly, Sarah
Acharya, Samita
Maharjan, Shreekrishna
Shrestha, Ashis
Pandey, Bimal
Lama, Mipsang
Shrestha, Ira
Voysey, Merryn
Eordogh, Agnes
Shrestha, Sonu
Feng, Elaine Shuo
Li, Grace
Shah, Ganesh
Pollard, Andrew J
Shrestha, Shrijana
author_facet Bijukchhe, Sanjeev M
O'Reilly, Peter J
Theiss-Nyland, Katherine
Gurung, Meeru
Pokhrel, Bhishma
Kelly, Sarah
Acharya, Samita
Maharjan, Shreekrishna
Shrestha, Ashis
Pandey, Bimal
Lama, Mipsang
Shrestha, Ira
Voysey, Merryn
Eordogh, Agnes
Shrestha, Sonu
Feng, Elaine Shuo
Li, Grace
Shah, Ganesh
Pollard, Andrew J
Shrestha, Shrijana
author_sort Bijukchhe, Sanjeev M
collection PubMed
description INTRODUCTION: Inactivated, viral vector and mRNA vaccines have been used in the Nepali COVID-19 vaccination programme but there is little evidence on the effectiveness of these vaccines in this setting. The aim of this study is to describe COVID-19 vaccine effectiveness in Nepal and provide information on infections with SARS-CoV-2 variants. METHODS AND ANALYSIS: This is a hospital-based, prospective test-negative case–control study conducted at Patan Hospital, Kathmandu. All patients >18 years of age presenting to Patan Hospital with COVID-19-like symptoms who have received a COVID-19 antigen/PCR test are eligible for inclusion. The primary outcome is vaccine effectiveness of licensed COVID-19 vaccines against laboratory-confirmed COVID-19 disease. After enrolment, information will be collected on vaccine status, date of vaccination, type of vaccine, demographics and other medical comorbidities. The primary outcome of interest is laboratory-confirmed SARS-CoV-2 infection. Cases (positive for SARS-CoV-2) and controls (negative for SARS-CoV-2) will be enrolled in a 1:4 ratio. Vaccine effectiveness against COVID-19 disease will be analysed by comparing vaccination status with SARS-CoV-2 test results. Positive SARS-CoV-2 samples will be sequenced to identify circulating variants and estimate vaccine effectiveness against common variants. Measuring vaccine effectiveness and identifying SARS-CoV-2 variants in Nepal will help to inform public health efforts. Describing disease severity in relation to specific SARS-CoV-2 variants and vaccine status will also inform future prevention and care efforts. ETHICS AND DISSEMINATION: Ethical approval was obtained from the University of Oxford Tropical Ethics Committee (OxTREC) (ref: 561-21) and the Patan Academy of Health Sciences Institutional Review Board (ref: drs2111121578). The protocol and supporting study documents were approved for use by the Nepal Health Research Council (NHRC 550-2021). Results will be disseminated in peer-reviewed journals and to the public health authorities in Nepal.
format Online
Article
Text
id pubmed-10123857
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101238572023-04-24 COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing Bijukchhe, Sanjeev M O'Reilly, Peter J Theiss-Nyland, Katherine Gurung, Meeru Pokhrel, Bhishma Kelly, Sarah Acharya, Samita Maharjan, Shreekrishna Shrestha, Ashis Pandey, Bimal Lama, Mipsang Shrestha, Ira Voysey, Merryn Eordogh, Agnes Shrestha, Sonu Feng, Elaine Shuo Li, Grace Shah, Ganesh Pollard, Andrew J Shrestha, Shrijana BMJ Open Public Health INTRODUCTION: Inactivated, viral vector and mRNA vaccines have been used in the Nepali COVID-19 vaccination programme but there is little evidence on the effectiveness of these vaccines in this setting. The aim of this study is to describe COVID-19 vaccine effectiveness in Nepal and provide information on infections with SARS-CoV-2 variants. METHODS AND ANALYSIS: This is a hospital-based, prospective test-negative case–control study conducted at Patan Hospital, Kathmandu. All patients >18 years of age presenting to Patan Hospital with COVID-19-like symptoms who have received a COVID-19 antigen/PCR test are eligible for inclusion. The primary outcome is vaccine effectiveness of licensed COVID-19 vaccines against laboratory-confirmed COVID-19 disease. After enrolment, information will be collected on vaccine status, date of vaccination, type of vaccine, demographics and other medical comorbidities. The primary outcome of interest is laboratory-confirmed SARS-CoV-2 infection. Cases (positive for SARS-CoV-2) and controls (negative for SARS-CoV-2) will be enrolled in a 1:4 ratio. Vaccine effectiveness against COVID-19 disease will be analysed by comparing vaccination status with SARS-CoV-2 test results. Positive SARS-CoV-2 samples will be sequenced to identify circulating variants and estimate vaccine effectiveness against common variants. Measuring vaccine effectiveness and identifying SARS-CoV-2 variants in Nepal will help to inform public health efforts. Describing disease severity in relation to specific SARS-CoV-2 variants and vaccine status will also inform future prevention and care efforts. ETHICS AND DISSEMINATION: Ethical approval was obtained from the University of Oxford Tropical Ethics Committee (OxTREC) (ref: 561-21) and the Patan Academy of Health Sciences Institutional Review Board (ref: drs2111121578). The protocol and supporting study documents were approved for use by the Nepal Health Research Council (NHRC 550-2021). Results will be disseminated in peer-reviewed journals and to the public health authorities in Nepal. BMJ Publishing Group 2023-04-18 /pmc/articles/PMC10123857/ /pubmed/37072367 http://dx.doi.org/10.1136/bmjopen-2022-068334 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Public Health
Bijukchhe, Sanjeev M
O'Reilly, Peter J
Theiss-Nyland, Katherine
Gurung, Meeru
Pokhrel, Bhishma
Kelly, Sarah
Acharya, Samita
Maharjan, Shreekrishna
Shrestha, Ashis
Pandey, Bimal
Lama, Mipsang
Shrestha, Ira
Voysey, Merryn
Eordogh, Agnes
Shrestha, Sonu
Feng, Elaine Shuo
Li, Grace
Shah, Ganesh
Pollard, Andrew J
Shrestha, Shrijana
COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing
title COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing
title_full COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing
title_fullStr COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing
title_full_unstemmed COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing
title_short COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing
title_sort covid-19 vaccine effectiveness and variants in nepal: study protocol for a test-negative case–control study with sars-cov-2 genetic sequencing
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123857/
https://www.ncbi.nlm.nih.gov/pubmed/37072367
http://dx.doi.org/10.1136/bmjopen-2022-068334
work_keys_str_mv AT bijukchhesanjeevm covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT oreillypeterj covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT theissnylandkatherine covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT gurungmeeru covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT pokhrelbhishma covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT kellysarah covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT acharyasamita covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT maharjanshreekrishna covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT shresthaashis covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT pandeybimal covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT lamamipsang covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT shresthaira covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT voyseymerryn covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT eordoghagnes covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT shresthasonu covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT fengelaineshuo covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT ligrace covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT shahganesh covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT pollardandrewj covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing
AT shresthashrijana covid19vaccineeffectivenessandvariantsinnepalstudyprotocolforatestnegativecasecontrolstudywithsarscov2geneticsequencing